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MITCHELL (1948) recently reported a clinical study on the use of parenterally
administered tetra-sodium 2-methyl-I: 4-naphthohydroquinone diphosphate
(synkayvite) as an adjuvant to radiotherapy in the management of inoperable
and far advanced malignant disease. In a small series he noted prolongation
of the mean survival time ofpatients with inoperable carcinoma of the bronchus
treated by the combination of chemical agent and irradiation when compared
with that of patients who received X-ray therapy alone, which he found to be
statistically significant.
The rationale for Mitchell's (1948) selection of this drug for clinical trial in
combination with radiotherapy depended upon his observation that the chemical
compound produced mitotic inhibition of chick fibroblasts in tissue culture.
Although there have been many laboratory studies on synkayvite as a vitamin
K substitute, no investigations have been published on the effect ofthis compound
on experimental neoplasms. On the basis of the claims made by Mitchell, it was
considered ofinteresttodeterminewhethersynkayvitealonehadanydemonstrable
effect on a variety of malignant tumours in experimental animals in order to
provide a basis for clinical trials with the agent. This report will present the
results of such experiments on four transplantable mouse tumours (three adeno-
carcinomas of the breast and an undifferentiated sarcoma), and the Brown-
Pearce carcinoma in rabbits (undifferentiated squamous cell carcinoma).
MATERIALS AND METHODS.
Preliminary chronic toxicity studies in mice were performed in the usual
way to determine the maximal tolerated dose on which the animals could continue
to maintain their body weight. Similar determinations were made in rabbits.
All of the mouse tumours were transplanted subcutaneously in the axillary
region by the trocar method. The intraperitoneal administration of synkayvite
was initiated 24 hou-rs after transplantation, and continued daily for theduration
of the experiment. Synkayvite was generously supplied by the Medical Division
of Hoffman-La Roche, Inc., Nutley, N.J. The growth of the tumours in control
and treated animals was followed by serial mensuration ofthe outside diameters,
but the conclusions reached in this study rest on the comparison of the wet
weight of the tumours in the control and treated series determined at theA. GELLHORN AND T. GAGLIANO
termination of the experiment. All tumours were prepared for histological
examination.
The effect of intraperitoneally injected synkayvite on the Brown-Pearce
carcinoma was determined on transplants of the tumour in the anterior chamber
of the eye in rabbits. This is a very convenient method for studying the action
of potential chemotherapeutic agents on this tumour, inasmuch as the fragments
grow uniformly, and completely fill the anterior chamber ofthe eye in 9-12 days.
The growth of the tumour can be readily charted at daily intervals, and at the
terrmination of the experiment the tumour, together with the infiltrated iris, is
removed and weighed so that an objective, quantitative comparison between
control and treated animals can be made. Results of the action of another
compound on the Brown-Pearce carcinoma studied in this way have been
reported (Gellhorn, Engleman, Shapiro, Graff and Gillespie, 1950).
RESULTS.
The toxicity experiments on mice and rabbits were inot exhaustively pursued
because, as will be seen, the results on the neoplasms failed to indicate any
significant effect following the administration of synkayvite.
The results of experimental chemotherapy with synkayvite on a variety of
neoplasms are summarized in Table I. From the information included it is
possible to estimate with accuracy the actual protocols for the individual experi-
ments, even though the pertinent results are here summarized as averages;
the standard deviation has been calculated in each instance in order to describe
the range and the distribution of the individual tumour weights about the mean
tumour weight. The standard deviation of the mean which is necessary for the
determination ofstatistical significance between two means is derived by dividing
the standard deviation by the square root of the number of observations.
In several ofthe experiments 5-amino-7-hydroxy-1-H-v-triazolo [d] pyrimidine
(8-azaguanine) was also administered to tumour-bearing animals for purposes of
comparison with synkayvite. A complete report ofour results with this chemical
compound has been published (Gellhorn, Engleman, Shapiro, Graff and Gillespie,
1950). As can be seen from the tabular material, no significant difference was
observed between the tumour weights of control and synkayvite treated mice.
Statistical analysis of the results of synkayvite treatment in rabbits with the
Brown-Pearce tumour was not made because ofthe smallnumberofobservations;
however, it is immediately apparent that no effect was demonstrable.
Careful study ofmicroscopic sections did not show any morphological changes
which distinguished the tumours from control and treated animaJs.
DISCUSSION.
From the results presented in the foregoing section it must be concluded that
synkayvite completely fails to inhibit the growth ofthree different types ofmouse
breast carcinomas, an undifferentiated squamous cell carcinoma in rabbits, and
an undifferentiated sarcoma in mice. In the absence of any demonstrable
carcinolytic or carcinostatic activity against experimental neoplasms the appli-
cation of synkayvite alone in the therapy of human cancer would appear to be
questionable. Although it is recognized that the parallelism between human
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neoplastic disease and malignant tumours in experimental animals is an unsettled
issue, it is important to note that, thus far, all of the chemotherapeutic agents
which have a demonstrable palliative effect against neoplasms in man have also
been shown to inhibit comparable tumours in laboratory animals.
It is also appreciated that the observations which we have recorded do not
duplicate in the laboratory the clinical experiments of Mitchell (1948), inasmuch
as he studied the combination of radiotherapy and the drug whereas -we investi-
gated the drug alone. Evaluation of combination therapy, however, utilizing
radiant energy plus a chemical compound, is not feasible in studies on experi-
mental neoplasms due to the ease with which X rays alone can destroy sub-
cutaneous tumours. Therefore, in spite ofnegative experimental evidence of the
typepresented inthisreport, thepossibilityremains thatsynkayvitein combination
with radiotherapy may produce a greater carcinolytic effect than X-ray therapy
alone. On examination of the available clinical evidence, it is difficult to assess
the contribution offered by the therapeutic regimen of synkayvite and radio-
therapy.
In Mitchell's (1948) report 73 patients with various types of advanced
malignant tumours received intramuscular injections of the drug in combination
with X-ray. Of this group, at least 23 patients were considered to have had an
unexpectedly good palliative response to irradiation. However, since these
cases included cancers of the mouth, lip, larynx, post-cricoid region, breast,
tongue, nasal fossa and skin together with one osteosarcoma of the ilium, and
since no criteria were recorded on which the designation of " unexpectedly good
palliative response " was based, it is impossible to evaluate the results objec-
tively. In another group of 10 patients representing a variety of advanced
malignant diseases, the compound was administered intravenously and was the
only form of therapy. Four of the individuals in this group experienced sub-
jective relief, but no indication that the fundamental course of the disease had
been altered by the therapy was indicated.
The main evidence for Dr. Mitchell's conclusion, that "tetra-sodium 2-methyl-
1: 4-naphthohydroquinone diphosphate in large doses produces a small but
useful improvement in the palliative results of X-ray therapy in some cases of
advanced cancer," rests on the results ofcombined treatment of9 cases ofbroncho-
genic carcinoma compared to 13 other patients with this disease treated by
X-ray alone. In this group the mean survival time after the institution of
radiotherapy or chemo- plus radio-therapy was 4*23 months for the controls and
7-56 months for the experimentals. The difference in the survival time was
found to be significantly different by statistical methods. Before interpreting
the mathematical analysis as an indication of biological significance, it must be
recognized that the validity of the statistical technique rests on certain factors
which, in this particular problem, include the assumptions that the probable
duration ofthe disease was similar in the control and experimental series, that the
histological types ofneoplasm (which are known to influence the rapidity of pro-
gression of the tumours) were appropriately balanced between the two groups,
and that other organic diseases which could influence the survival time played
no part in the results. It is, of course, possible that these several variables were
adequately controlled; however, in the absence'of documentation in the report,
the statistical evaluation of the clinical results can not be accepted without
qualification.
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SUMMARY AND CONCLUSIONS.
The effect of the vitamin K substitute tetra-sodium 2-methyl-1I 4-naphtho-
hydroquinone diphosphate (synkayvite) on the growth of five malignant, trans-
plantable tumours in experimental animals was determined. No inhibitory
action on three different types of adenocarcinoma of the breast, one undifferen-
tiated squamous-cell carcinoma and one undifferentiated sarcoma could be
demonstrated. There were no morphological changes in the tumours of animals
treated with synkayvite which distinguished them from tumour sections of
untreated control animals.
This work was supported by a grant from the American Cancer Society on
the recommendation of the Committee on Growth of the National Research
Council.
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